期刊
CLINICAL CANCER RESEARCH
卷 28, 期 22, 页码 4849-4860出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-21-1564
关键词
-
类别
资金
- LaCaixa Foundation [100010434]
- Instituto de Salud Carlos III [PI17/01527]
- European Regional Development Fund (ERDF)
- [LCF/BQ/DR21/11880015]
Immunotherapy has revolutionized the treatment of endometrial cancer by targeting different molecular subtypes and tumor microenvironment features.
Immunotherapy with checkpoint inhibitors has changed the paradigm of treatment for many tumors, and endometrial carcinoma is not an exception. Approved treatment options are pembrolizumab or dostarlimab for mismatch repair deficient tumors, pembrolizumab for tumors with high mutational load, and, more recently, pembrolizumab/lenvatinib for all patients with endometrial cancer. Endometrial cancer is a heterogeneous disease with distinct molecular subtypes and different prognoses. Differences between molecular subgroups regarding antigenicity and immunogenicity should be relevant to develop more tailored immunotherapeutic approaches. In this review, we aim to summarize and discuss the current evidence-Facts, and future opportunities-Hopes-of immunotherapy for endometrial cancer, focusing on relevant molecular and tumor microenvironment features of The Cancer Genome Atlas endometrial cancer subtypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据